Literature DB >> 15170666

The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations.

Raquel Rodríguez-López1, Ana Osorio, Gloria Ribas, Marina Pollán, Luis Sánchez-Pulido, Miguel de la Hoya, Alvaro Ruibal, Pilar Zamora, Jose Ignacio Arias, Raquel Salazar, Ana Vega, Jose Ignacio Martínez, Eva Esteban-Cardeñosa, Carmen Alonso, Rocío Letón, Miguel Urioste Azcorra, Cristina Miner, M Eugenia Armengod, Angel Carracedo, Rogelio González-Sarmiento, Trinidad Caldés, Orland Díez, Javier Benítez.   

Abstract

Six SNPs have been detected in the DNA repair genes RAD51C and RAD51D, not previously characterized. The novel variant E233G in RAD51D is more highly represented in high-risk, site-specific, familial breast cancer cases that are not associated with the BRCA1/2 genes, with a frequency of 5.74% (n = 174) compared to a control population (n = 567) and another subset of breast cancer patients (n = 765) with a prevalence of around 2% only (comparison to controls, OR = 2.6, 95% CI 1.12-6.03; p < 0.021). We found that the immunohistochemical profile detected in available tumors from these patients differs slightly from those described in non-BRCA1/2 tumors. Finally, the structural prediction of the putative functional consequence of this change indicates that it can diminish protein stability and structure. This suggests a role for E233G as a low-penetrance susceptibility gene in the specific subgroup of high-risk familial breast cancer cases that are not related to BRCA1/2. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170666     DOI: 10.1002/ijc.20169

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India.

Authors:  Ashraf U Mannan; Jaya Singh; Ravikiran Lakshmikeshava; Nishita Thota; Suhasini Singh; T S Sowmya; Avshesh Mishra; Aditi Sinha; Shivani Deshwal; Megha R Soni; Anbukayalvizhi Chandrasekar; Bhargavi Ramesh; Bharat Ramamurthy; Shila Padhi; Payal Manek; Ravi Ramalingam; Suman Kapoor; Mithua Ghosh; Satish Sankaran; Arunabha Ghosh; Vamsi Veeramachaneni; Preveen Ramamoorthy; Ramesh Hariharan; Kalyanasundaram Subramanian
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

2.  The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.

Authors:  Michael Zeidler; Sooryanarayana Varambally; Qi Cao; Arul M Chinnaiyan; David O Ferguson; Sofia D Merajver; Celina G Kleer
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

3.  DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.

Authors:  Marie Ollier; Nina Radosevic-Robin; Fabrice Kwiatkowski; Flora Ponelle; Sandrine Viala; Maud Privat; Nancy Uhrhammer; Dominique Bernard-Gallon; Frédérique Penault-Llorca; Yves-Jean Bignon; Yannick Bidet
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

4.  Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma.

Authors:  Yan-Ji Jiang; Jian-Hong Zhong; Zi-Han Zhou; Mo-Qin Qiu; Xian-Guo Zhou; Ying-Chun Liu; Rong-Rui Huo; Xiu-Mei Liang; Zhu Chen; Qiu-Ling Lin; Xiang-Yuan Yu; Hong-Ping Yu
Journal:  Cancer Med       Date:  2019-03-18       Impact factor: 4.452

5.  Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.

Authors:  A Smith; A Moran; M C Boyd; M Bulman; A Shenton; L Smith; R Iddenden; E R Woodward; F Lalloo; E R Maher; D G R Evans
Journal:  J Med Genet       Date:  2006-11-01       Impact factor: 6.318

6.  Functional characterization and identification of mouse Rad51d splice variants.

Authors:  Aaron M Gruver; Brian D Yard; Campbell McInnes; Changanamkandath Rajesh; Douglas L Pittman
Journal:  BMC Mol Biol       Date:  2009-03-27       Impact factor: 2.946

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.